MIMS Group, an Asia-Pacific provider of medicines information, clinical decision support, medical communications, and marketing services, is accelerating product innovation and international growth as it transforms its long-standing healthcare data, content, and market expertise into new technology platforms, customer applications, and services. The announcement, made via Media OutReach Newswire, signals a strategic shift for the global healthcare technology company anchored by six decades of trusted medical data and expertise.
Following the appointment of Sohil Goswami as Group CEO in January 2026, MIMS has reshaped its businesses and leadership structure to support its next phase of growth. The company is now ready to harness its data, technology, and healthcare relationships to create scalable products and new business models across markets.
Central to this evolution is the expansion of MIMS' Clinical Decision Support (CDS) offerings. MIMS recently launched MIMS Pulse, its next-generation CDS platform that combines MIMS' medicines data and clinical knowledge with modern technology, flexible deployment, and integration capabilities to support safer and more efficient clinical workflows. Alongside MIMS Pulse, the company is scaling eMIMS Plus, a platform that brings MIMS' trusted medicines information into a modern digital experience designed to achieve quality use of medicine. Conceived and first launched in Australia under Goswami's guidance in his previous role leading the CDS Business, eMIMS Plus is now available in India and Malaysia with plans to expand across Southeast Asia, introduce new clinical modules, and extend into new healthcare categories through Drugs4Dent.
MIMS is also developing its global CDS offering, building on MIMS Pulse and eMIMS Plus to take its clinical data and technology capabilities into new markets and customer environments. This expansion could have significant implications for healthcare professionals worldwide, providing them with advanced tools to make more informed decisions and improve patient outcomes.
Simultaneously, MIMS' Medical Communications business is expanding internationally, with commercial capabilities in the US and UK creating opportunities with new client segments and global life sciences organizations. The business continues to develop digital events, AI-enabled content capabilities, and new customer engagement models. MIMS is exploring more connected, intelligence-led services – helping healthcare and life sciences organizations better understand their markets, engage healthcare professionals, and make more informed decisions. This work represents an important step beyond MIMS' traditional information and communications models, applying its content data and market reach to new technology-enabled services.
Goswami said: "For decades, healthcare professionals have trusted MIMS' medicines information and expertise. Today, we are transforming that foundation into the next generation of digital products, platforms, and services. We have been reshaping the business – bringing our capabilities together, strengthening our technology, and building new ways to serve customers across markets. Our opportunity is to turn trusted medical data, deep healthcare relationships, and market knowledge into the next generation of products, platforms, and services to build a MIMS that can compete and grow globally while staying relevant to the markets we serve."
The developments form part of a broader evolution across MIMS as the company builds on its established strengths while extending its products, capabilities, and reach into new areas of healthcare. For the healthcare industry, MIMS' move underscores the growing role of AI and digital platforms in clinical decision support and medical communications, potentially raising the bar for data-driven care and commercial engagement. For readers, this means access to more sophisticated, reliable tools that can enhance clinical practice and patient care. MIMS is present in 17 markets globally with over two million healthcare professional subscribers. Learn more at https://corporate.mims.com/.
